Specific binding proteins (BPS) to somatomedin/insulin-like growth factors (Sm/lGFs) have been identified in conditioned media from a variety of cells in culture. By affinity crosslinking using disuccinimidyl suberate, we have covalently cross-linked radiolabeled somatomedin-C/insulin-like growth factor I (Sm-C/IGF I), insulin-like growth factor II (IGF II) and insulin to BPS in conditioned medium (CM) from cultured astroglial cells derived from cerebral cortices of neonatal rats. Two species of radiolabeled Sm/lGF BP complexes of 40,000 Da (40K) and 45K were identified.
Competition with unlabeled Sm-C/IGF I and IGF II demonstrated that the BPS in each complex have similar affinities for Sm-C/IGF I and IGF II. The BP in the 45K complex was about L-fold more sensitive to competition with unlabeled Sm/lGFs than the BP in the 40K complex, suggesting that it either has a higher affinity for Sm/lGFs or is less abundant.
Evidence that the BPS in each complex are distinct includes the following findings: (1) insulin competed with Sm/lGF for binding to the 45K complex, but not the 40K complex, and (2) the BP in the 40K complex, but not the 45K complex, was recognized by antibodies raised against a BP purified from CM of buffalo rat liver (BRL) 3A cells. Growth hormone did not affect the apparent secretion of either BP. The binding activity of both BPS was retained after mild heat treatment, changes to extremes of pH (2-lo), and prolonged storage at -2O"C, but was destroyed after heating to higher temperatures (80% and greater), reduction, and proteolytic treatment. Neither BP appeared to be glycosylated because treatment with endoglycosidase-F resulted in no change in the apparent sizes of the complexes or in their capacity to bind Sm/lGFs. Identification of the BPS by a modified Western blotting technique, involving transfer of electrophoretically separated BPS to nitrocellulose membrane and binding with 1Z51-Sm/lGF, revealed BPS of about 38K and 33K Da, indicating that one molecule of BP bound to one molecule of Sm/lGF. Using the BP purified from BRL-3A CM as a surrogate for the 33K astroglial BP, we found that it reduced Sm-C/IGF l-stimulated 3H-thymidine incorporation by astroglial cells in a dose-dependent manner by binding Sm-C/IGF I and reducing its availability to the cell surface receptors. The latter findings suggest that the 33K BP may modulate Sm/lGF I's growthstimulating actions on astroglia. Interactions among Sm/lGFs, their binding proteins, and receptors may represent a regulatory mechanism for the control of glial growth.
Somatomedins or insulin-like growth factors (Sm/IGFs) circulate in blood bound to specific binding proteins (BPS) (for reviews, see Clemmons and Van Wyk, 198 1; Hintz, 1984; Smith, 1984; Nissley and Rechler, 1984) . In human plasma, 2 major forms of Sm/IGF-BP complexes exist: an approximately 150,000 Da (15OK) species that is under growth hormone (GH) control, and a smaller species that is independent of GH and has a molecular weight variously estimated to be between 30 and 50K. In the rat, similarly sized plasma Sm/IGF-BP complexes are observed by gel chromatography (Moses et al., 1976) . In both human and rat, the GH-independent 30-50K species has been shown to be proportionately higher in fetal than in adult plasma (D'Ercole et al., 1980; White et al., 1982; Drop et al., 1984b) . Such Sm/IGF BPS have been demonstrated in human amniotic fluid (Chochinov et al., 1977; Bala et al., 1978; Drop et al., 1979 Drop et al., , 1984a Grizzard et al., 1984) , in conditioned media (CM) from human fibroblasts (Atkison et al., 1980; Clemmons et al., 198 1, 1986) , liver explants (Rechler et al., 1979; Binoux et al., 1980) cloned buffalo rat liver (BRL-3A) cells Knauer et al., 1981; Romanus et al., 1986; Mottola et al., 1986) human hepatoma cells (Moses et al., 1983) , fetal mouse limb bud explant cultures (D'Ercole et al., 1980 ) pancreatic beta cells (Romanus et al., 1986) , and pituitary and brain explant cultures (Binoux et al., 1981) . These findings suggest that Sm/ IGF BPS are produced by a variety of tissues in vitro and probably in vivo. The physiological functions of Sm/IGF BPS are unclear. It has been suggested that BPS, by virtue of their capacity for binding Sm/IGFs, may regulate the release of these peptides at their sites of action, and thereby control the biologic function of Sm/IGFs (Nissley et al., 1977; Drop et al., 1979; Knauer and Smith, 1980; Hintz, 1984) . While studying the effects of Sm/ IGFs on purified polygonal astroglial cells from neonatal rat cerebral cortices, we have identified and characterized 2 distinct species of Sm/IGF BP secreted into culture medium by these cells. Using a BP purified from CM of BRL-3A cells, which is immunologically similar to one of the astroglial BPS character-ized in this studv. we have shown that the BP inhibits the mian additional 0 (2 min), 6, 12, 18, 24, 36 , and 48 hr. CM was collected and stored frozen at -20°C.
togenic action ofSm/IGFs on astroglial cells by competing with the Sm/IGF receptors for Sm/IGF binding.
Materials and Methods
Materials. Sm-C/IGF I and IGF II were purified from Cohn fraction IV of human plasma, as previously described Svoboda and Van Wyk, 1985) . Multiplication-stimulating activity (MSA) III-2 was a kind gift of Dr. S. Peter Nissley, NCI, and insulin was a gift of Dr. M. Root, from E. Lilly. The peptides were iodinated with NalZSI (New England Nuclear, Boston, MA) according to a modification of the chloramine-T method (Furlanetto et al., 1977) to specific activities ranging from 200 to 250 &i/pg. The iodinated Sm-C/IGF I was further purified by immunoaffinity chromatography and the other iodinated peptides by gel filtration on a Sephadex G-50 column in 1 M acetic acid, as previously described . The iodinated peptides were stored in 1 M acetic acid at -70°C and used for the studies within 2 weeks of iodination. Just prior to use, the iodinated peptides were neutralized with 1 M sodium hydroxide to pH 7.0. Human growth hormone (hGH) was a gift from Kabi Vitrum (Stockholm, Sweden). The Sm/IGF BP was purified from CM of BRL-3A cells, and antibodies were raised against it, as previously described (Mottola et al., 1986) . Both were the generous gift of Dr. Christina Mottola and Michael Czech (The University of Massachusetts Medical Center, Worcester, MA).
~ZSI-Sm/IGFafinitycross-linkingstudies.
A modification ofthe method described by Wilkins and D'Ercole (1985) was used to affinity crosslink 1251-Sm/IGFs to binding proteins in astroglial CM. CM, either unconcentrated (50 ~1) or concentrated 110 ~1 of 20 x CM, concentrated by centrifugation in Centricon micro~oncentrators (Amicon, Danvers, MA) with 10K Da A4, cutoff membrane], was incubated for 30 min with 1251-Sm-C/IGF I, IGF II, or insulin (250,000 cpm/tube, 100 fmol) in 100 mM HEPES containing 12 M NaCl, 5 mM KCl, 1.2 mM MgSO,, and 8 mr.,r dextrose, pH 7.4 (HEPES buffer) to a final reaction volume of 100 ~1 at 4°C with or without varying concentrations of unlabeled peptides. Cross-linking was accomplished by the addition of 5 ~1 of 10 mM disuccinimidyl suberate (DSS; Pierce Chemicals, Rockford, IL) dissolved in dimethyl sulfoxide (DMSO) to give a final concentration of 0.5 mM DSS. followed by incubation at room temperature for 10 min. The cross-linking reaction was stopped and the proteins were solubilized by the addition of 20 ~1 of 5 x gel sample buffer (62.5 mM TrisHCl, pH 8.8, 5% SDS, 0.0 1% bromophenol blue, and 40% glycerol) with or without the reducing agent 2-mercaptoethanol (lO%), and boiled for 3 min.
Affinity cross-linking of 1251-Sm-C/IGF I to receptors on astroglial cells was performed as previously described (Han et al., 1987) . Briefly, purified astroglial cells were plated on 35 mm tissue culture dishes and cultured to confluence. The medium was reolaced with SF-BME and cultured for another 48 hr. The cells were washed with 100 mM HEPES buffer, pH 8.0, with BSA 10 mg/ml, and incubated with 1251-Sm-C/IGF I (4-5 x lo5 cpm/dish) in fresh HEPES buffer, without or with varying concentrations of BRL-3A BP at 4°C for 16-18 hr. The incubation solution was then aspirated, and the cultures were washed 3 times with cold HEPES buffer. DH 7.4. without BSA. to remove the unbound radiolabel. The 1251-Sm-C/IGF I that was bound to cell surface receptors was affinity cross-linked with 0.1 M DSS at 22°C for 10 min. The reaction was stopped by aspiration of the DSS solution and addition of 1 ml of 10 mM Tris-HCl. The cells were scraped from the bottom of the dish using a disposable plastic spatula, solubilized in 2% SDS, 12.5 mM TrisHCl, 0.002% bromophenol blue, 8% glycerol, and 100 mM dithiothrietol (DTT), and boiled for 5 min.
Astroglial cultures and collection ofconditioned media. Relatively pure cultures of polygonal astroglial cells were prepared from cerebral cortices of 1 -d-old Sprague-Dawley rats (Charles River Breeding Laboratories, Wilmington, MA), as previously described (McCarthy and de Vellis, 1980; Han et al., 1987) . Briefly, l-d-old rats were decapitated and the brains removed aseptically. The cerebral cortices were dissected and the meningeal coverings carefully peeled off. The cortical tissue was cut into small pieces and incubated in 0.1 O/o trypsin and 0.02% EDTA solution (Gibco Laboratories. Grand Island, NY) at room temperature for 30 min with constant shaking. Trypsin activity was inhibited by the addition of twice the volume of basal medium Eagle (BME, Gibco) containing 10% fetal calf serum (FCS; Hyclone Sterile Systems, Logan, UT). The cell suspension was removed and filtered through a 130 pm Nitex monofilament screen (Tetko, Elmsford, NY). The remaining tissues were triturated mechanically and filtered, the filtrate was combined with the initial cell suspension and centrifuged at 2000 x g. The cell pellet was gently vortexed and resuspended in complete medium (BME with 10% FCS, 5 U/ml penicillin, and 5 &ml streptomycin). The number of viable cells was determined by the trypan blue-exclusion method in a hemacytometer (> 90% viable): A cell-suspension of 2.5-3 x 1 O6 live cells/ml was prepared and plated in 200 ml tissue culture flasks (75 cm2 growth area). The cells were cultured at 37°C in 5% CO, and 95% air with 100% humidity for 12-14 d, until confluence. The cells were then shaken at 270 rpm for 18 hr at 37"C, and the medium containing suspended cells was removed, discarded, and replaced with new complete medium. The resulting culture consisted of more than 95% flat polygonal astroglial cells, as confirmed by phase-contrast microscopy and positive immunostaining with the antibody against glial fibrillary acid protein (GFAP; McCarthy and de Vellis, 1980 ). The remaining < 5% of cells consisted of process-bearing cells (about half of which were astrocytes and half oligodendrocytes), ependymal cells, and fibroblasts. Therefore, even though we cannot exclude some contribution towards the total BP content of the CM by the nonastrocytic cells, we believe that the major portion of the total BP content of the CM was secreted by the polygonal astrocytes.
The samples were then subjected to SDS-PAGE on 6-14% linear gradient gels for CM BPS, and 3-14% linear gradient gels for astroglial cell membrane receptors, using a Tris-glycine buffer, pH 8.0, according to the method of Laemmli (1970) . Gels were then fixed in 10% acetic acid and 30% methanol solution, washed, dried, and exposed to x-ray film (Kodak XAR or XRP) between 2 intensifying screens (DuPont Chemical, Wilmington, DE) at -70°C for 3-7 d. The M,s of the standards used for SDS-PAGE were myosin (200,000 Da), phosphorylase B (97,400 Da), BSA (68,000 Da), ovalbumin (43,000 Da), alpha chymotrypsin (25,700 Da), beta lactglobulin (18,400 Da), and lysozyme (14,300 Da) (Bethesda Research Laboratories, Bethesda, MD).
The cultures were used within 1 week of "purification" and at least 1 d after the medium change. After purification, cells in 200 ml flasks were washed twice with serum-free BME (SF-BME) and incubated in 20 ml of fresh SF-BME for 24 hr at 37°C. The medium was aspirated and replaced with 20 ml of SF-BME containing 2 mg/ml BSA (Sigma, lot no. 122F-0890, which contained no Sm-CYIGF I by radioimmunoassay) and incubated at 37°C. CM was collected after 48 hr and stored frozen at -20°C. This CM was used for characterization studies. For studies of the time course of BP elaboration, astroglial cells were subplated into 48-well tissue culture plates (1 cm2 growth area/well; Costar, Cambridge, MA), at cell densities of 0.12 x 1 O6 cells/well, in BME with 10% FCS, and cultured until confluence (usually for 48 hr). Cells were then washed twice with SF-BME, incubated in fresh SF-BME for 24 hr, and then in either SF-BME or SF-BME containing 2 mg/ml BSA for Binding of 12SI-Sm-C/IGF I to binding proteins after transfer to nitrocellulose membrane. Concentrated (20 x) astroglial CM, 50 ~1, was incubated in 10 ~1 of gel sample buffer 5 times at 50°C for 1 hr and the proteins separated on a 6-14% linear gradient SDS-PAGE, as above. This was followed by electrophoretic transfer to nitrocellulose (NC) membrane (pore size, 0.45 pm; New England Nuclear, Cambridge, MA) on an electrophoretic blotting apparatus (Trans-Blot System; Bio-Rad, Richmond, CA) for 500 V hr in Tris-glycine-methanol buffer, pH 7.4. After brief washing in this buffer, the NC membrane was air-dried for 30 min, enclosed in a Micro-Seal plastic bag (Dazey, Industrial Airport, KS), and incubated in 0.1 M HEPES buffer, pH 7.4, containing 0.12 M NaCl, 5 mM KCl, 1.2 mM MgSO,, 8 mM dextrose, at room temperature for 1 hr with constant shaking. This solution was replaced with fresh buffer containing 1251-Sm-C/IGF I (0.5 x lo6 cpm/ml) and incubated at room temperature for 1 hr. The NC membrane was removed from the bag and washed thoroughly with Tris-saline buffer containing 0.02% Nonidet-P 40 (Sigma) for 2 hr, with several changes of wash buffer, until the buffer was devoid of radiolabel. The NC membrane was airdried for 30 min and exposed to x-ray film (Kodak XRP-5) at -70°C for 4-8 hr. A similar technique has been used to analyze Sm/IGF BPS in human serum (Hossenlopp et al., 1986) .
Immunoprecipitation of afinity-labeled BPS. Ten microliters of 20 x concentrated CM in 10 mM HEPES buffer was affinity-labeled with 1251-Sm-C/IGF I, as described above (final reaction vol, 100 ~1). To this solution, 25 ~1 of BRL-3A antibodies (F or P) or control preimmune antibody (C) was added to achieve a final dilution of 1: 100 and incubated at 4°C for 18-20 hr (the antibodies were partially purified by precipitating antisera with 30% ammonium sulfate, and followed by dialysis and lyophilization). Sheep anti-rabbit antiserum (15 & Wellcome Laboratories, Beckinham, UK) was added to each sample and incubated for another 2 hr at room temperature. Finally, 10 ~1 of normal rabbit serum was added to each sample and incubated for 2 hr at 4°C. Immunoprecipitates were collected by centrifugation in a microcentrifuge for 5 min and washed twice with phosphate buffer, pH 7.4. Immunoprecipitates were solubilized in 50 ~1 gel sample buffer (62.5 mM TrisHCl, pH 6.8, 1% SDS, 8% glycerol, 0.1% bromophenol blue, and 2% 2-mercaptoethanol) and boiled for 3 min. Samples were subjected to 6-14% linear gradient SDS-PAGE and the gels were fixed, dried, and autoradiographed as described above. Astroglial receptor binding studies. Binding studies were performed on plated astroglial cells as previously described (Han et al., 1987) . Briefly, astroglial cells were plated on 48-well tissue culture plates and cultured until confluence. They were then incubated in SF-BME for 48 hr prior to incubation with lZSI-Sm-C/IGF I (50,000 cpm/well; 20 fmol) in 0.1 M HEPES binding buffer, pH 8.0, in the presence of graded concentrations of BRL-3A BP (5 @ml to 1 &ml) for 4 hr at 4°C. Nonspecific binding was determined as binding in the presence of an excess of unlabeled Sm-C/IGF I (10 &ml). Binding was terminated by aspiration of the incubating solution and washing the cultures thoroughly with cold PBS 3 times. The cells were solubilized with 0.1 N NaOH and 1% SDS for 15 min at room temperature, and the cell lysate was transferred to test tubes. The cell associated radioactivity was then determined in a gamma spectrometer (Hewlett-Packard, Corvallis, OR).
'H-Thymidine incorporation studies. The effects of BRL-3A BP on the mitogenic action of Sm-C/IGF I on astroglial cells was determined by 'H-thymidine incorporation assay, as previously described (Han et al., 1987) . Briefly, astroglial cells were plated on 48-well tissue culture plates and cultured to subconfluence (usually 48 hr). They were then incubated in SF-BME for 48 hr and exposed to 25 rig/ml Sm-C/IGF I with varying concentrations of the BRL-3A BP (O-l &ml). After incubation for 22 hr, 3H-thymidine (0.5 &i/well; New England Nuclear) was added to the cultures and the incubation was continued for another 2 hr. The reaction was stopped by aspiration of the incubating solution and washing with cold (4oC) PBS 3 times. The cultures were then incubated with 5% trichloracetic acid (TCA) at 4°C for 20 min. The TCA solution was aspirated and the cultures were washed again with fresh 5% TCA. After removal of the TCA solution, the cultures were solubilized in 0.1 N NaOH and 1% SDS. The resulting solution was added to 10 ml of complete counting cocktail (Research Products International, Elk Grove Village, IL) and counted in a scintillation counter (LKB Instruments, Gaithersburg, MD).
Results

Afinity-labeled SmLGF-BP complexes in astroglial CA4
When concentrated astroglial CM was affinity-labeled with lZ51-Sm-C/IGF I and analyzed by SDS-PAGE, 2 species of radiolabeled Sm-C/IGF I-BP complexes, with M,s of 45K and 40K were observed under reducing conditions (Fig. 1) . Under nonreducing conditions, 2 similar-sized species were observed, but the resolution of the 2 bands was inferior (not shown). These bands were judged to represent specific Sm/IGF-BP complexes because their intensity was diminished or obliterated when either unlabeled Sm-C/IGF I or IGF II (50 rig/ml) was present during the incubation. The 45K complex could be lessened in intensity by as little as 5 r&ml Sm-C/IGF I (not shown) or 10 r&ml IGF II, and obliterated by 20 rig/ml Sm-C/IGF I or 50 r&ml IGF II. Very high concentrations of insulin (10 &ml) could also compete for lZSI-Sm-C/IGF I binding. Approximately IO-fold higher concentrations of either Sm-C/IGF I or IGF II were required to compete for the binding in the 40K complex, while 10 &ml of insulin did not appear to compete for this binding. 
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The BP represented in the 45K complex, therefore, appears either to have a higher affinity for Sm/IGFs or to be less abundant than that in the 40K complex. A cross-linked band of M, about 68K was also radiolabeled, and represents nonspecific binding of radiolabeled Sm/IGF to the albumin contained in the medium (Wilkins and D'Ercole, 1985) . When astroglial CM was affinity cross-linked to lz51-IGF II, 2 identically sized protein bands were radiolabeled (Fig. 2) . These bands were nearly obliterated by incubation with 50 ng/ ml of unlabeled IGF II or Sm-C/IGF I. As with binding to L251-Sm-C/IGF I, low concentrations of unlabeled Sm/IGFs (10 ng/ ml) obliterated the 45K complex, while Sm/IGF concentrations of 50-100 rig/ml were required to obliterate the 40K complex. Unlabeled Sm-C/IGF I was equipotent to unlabeled IGF II in competing with radiolabeled IGF II for both binding proteins. As with 1251-Sm-C/IGF I binding, unlabeled insulin at very high concentrations (10 pg/ml) diminished the intensity of the 45K complex, but had no apparent effect on the 40K complex.
Afinity-labeled 1Z51-insulin-BP complexes in astroglial CM
When 1251-insulin was used as a radiolabel for affinity crosslinking with astroglial CM, a single 45K band of relatively low intensity was radiolabeled (Fig. 3) . The BP in this complex appeared to have a low affinity for L2SI-insulin because 10 pg/ ml of unlabeled insulin was required to diminish its intensity. There was no apparent competition with either Sm-C/IGF I or IGF II at concentrations of 100 @ml, suggesting that insulin was not bound to the same site as the Sm/IGFs. Studies of BP secretion CM collected by incubation of astroglial cells in SF-BME for 48 hr resulted in a decrease in the intensity of radiolabeled complexes, as compared to CM collected by incubation of astroglia with SF-BME containing BSA (data not shown). The latter finding suggests that BP synthesis is dependent on an exogenous protein source. To study the time course of secretion of the BPS, astroglial cultures were serum-starved for 48 hr, then incubated with SF-BME with BSA and CM collected at 6 hourly intervals. When CM were affinity cross-linked to 'ZSI-Sm-C/IGF I, both complexes were detectable at 6 hr, and progressively increased in apparent abundance. The 40K complex was more intensely labeled than the 45K complex at each time, suggesting that it is more rapidly synthesized and therefore more abundant. Incubation with hGH did not alter the apparent rate of synthesis of either BP.
Biochemical characteristics of the BPS
To further characterize these BPS, they were subjected to a variety of physicochemical treatments prior to affinity crosslinking with L251-Sm-C/IGF I. Heating of CM to 56°C for 2 hr, freezing at -20°C for up to 3 months, acidification (to pH 2), alkalinization (to pH lo), or incubation with endoglycosidase-F (l-l 00 U/ml; New England Nuclear) did not have apparent effects on L251-Sm-C/IGF I binding or on the size of the binding moieties. However, heating at temperatures of 80°C or higher for 5 min, reduction with 2-mercaptoethanol, and mild pro-26-1 L hsulin --1 w/ml teolytic treatment (e.g., 0.001% trypsin for 30 min) destroyed binding activity. These results are consistent with pH-stable, nonglycosylated proteins, which contain interchain disulfide bonds that are essential for binding.
Binding of 1251-Sm-C/IGF I to BPS transferred to nitrocellulose membrane
After transfer of electrophoretically resolved astroglial CM to nitrocellulose membrane and binding with 1251-Sm-C/IGF I, 2 radiolabeled bands with A4,s of 38-4OK and 33-35K were observed. These bands appear to represent the 45 and 43K BP complexes that were observed when conditioned medium was affinity cross-linked to 1251-Sm-C/IGF I prior to separation on SDS-PAGE (Fig. 4) . Because the M,s of the BPS thus identified correspond well with those of the affinity-labeled complexes minus the J4, of the radiolabeled ligand (45K -7K = 38K, and 40K -7K = 33K), these findings are consistent with the binding of a single molecule of Sm/IGF to each BP molecule.
Relationship between astroglial BPS and BRL-3A BP
Affinity labeling of the BP purified from BRL-3A cells with lzsISm-UIGF I revealed a single band of AJ, 40K, which could be obliterated by incubation with 100 rig/ml of unlabeled Sm-C/ IGF I (Fig. 7) . When astroglial BP was affinity-labeled with L2sI-Sm-C/IGF I and immunoprecipitated with antisera F and P, which were raised against BRL-3A BP, a single band of M, 40K was observed (Fig. 5) . A control preimmune rabbit serum (C) Eflects of BRL-3A BP on the mitogenic action of Sm-UIGF I Addition of 25 rig/ml Sm-C/IGF I stimulates 3H-thymidine incorporation of astroglial cells 4-fold above the basal conditions. 3H-Thymidine incorporation could be reduced by purified BRL-3A BP in a dose-dependent manner (Fig. 6) . Addition of BRL-3A BP to astroglial cells in the absence of Sm-C/IGF I did not alter the basal 3H-thymidine incorporation, suggesting that the effect of the BP is specific to the mitogenic action of Sm-CI IGF I on astroglia.
To determine whether the effect of BP on the mitogenic action of Sm-C/IGF I was due to competition with the Sm/IGF receptors for the peptide, increasing concentrations of the BP were added to a constant concentration of radiolabeled Sm-C/IGF I. The BRL-3A BP inhibited 1251-Sm-C/IGF I binding to astroglial cells in a dose-dependent manner (Fig. 7) . Moreover, the BP concentration causing half-maximal binding inhibition (77 ng/ ml) was nearly identical to the concentration resulting in halfmaximal inhibition of mitogenic response to Sm-C/IGF I (80 rig/ml). These findings strongly suggest that the BRL-3A BP inhibits the mitogenic actions of Sm-CYIGF I by competing with the receptor for the ligand. The latter conclusion is further supported by the affinity crosslinking studies. Affinity-labeling of the astroglial cell surface receptors with 1251-Sm-C/IGF I and analysis on SDS-PAGE under reducing conditions (Fig. 8) showed radiolabeled bands of M, 130K (alpha subunit of the type I Sm/IGF receptor), A4, 260K (type II Sm/IGF receptor) and M, > 300K (unreduced type I receptor). Specificity of binding of the radiolabel to these receptors has been shown previously (Han et al., 1987) . The addition of increasing concentrations of BRL-3A BP to the binding buffer prior to cross-linking diminished the intensity of all 3 bands, and at BP concentration of 1 &ml, radiolabeled receptor complexes were not observed (Fig. 8) . The reduction in the intensity of radiolabeled bands in the presence of increasing concentrations of BP correlated well with the inhibition of specific binding observed in the binding studies (Fig. 7) . These results indicate that the BP binds Sm-C/IGF I and prevents binding of Sm-C/IGF I to its cell surface receptors. Sm-C/IGF I is thus rendered biologically inactive. Similar findings were observed with radiolabeled IGF II (data not shown).
Discussion
By using DSS, we have covalently cross-linked radiolabeled Sm/ IGFs to specific binding moieties in CM from rat astroglial cells. Our evidence suggests that each is a pH-stable, nonglycosylated protein with interchain disulfide linkages capable of binding one molecule of either Sm-C/IGF I or IGF II with near-equal affinity. The BPS in these cross-linked complexes appear to have M,s of 38-40K and 33-35K Da, respectively.
Both Sm-UIGF I and IGF II (or MSA) appeared equipotent in competing for the binding to each of the BPS, suggesting that the Sm/IGFs share the same BPS. This is in agreement with our previous findings of rat serum BPS , as well as those of Moses et al. (1976) . That the 45K complex was about 5-fold more sensitive to competition by the Sm/IGFs than the 40K complex may reflect either differences in affinity or in the abundance of each BP. The techniques used do not distinguish between these possibilities.
Several lines of evidence indicate that the 45 and the 40K complexes represent distinct BPS: (1) The 40K cross-linked complex, but not the 45K complex, is recognized by antibodies against the BRL-3A BP. (2) The BP in the 45K complex recognizes insulin weakly, while that in the 40K complex does not. (3) Because endoglycosidase-F did not decrease the size of either complex, it is. unlikely that the BP in the 45K complex is a N-glycosylated form of the 40K species. And (4), our finding that the 2 BPS could be separated electrophoretically prior to binding with a radiolabeled ligand indicates that the 2 complexes do not represent the same BP bound to different numbers of Sm/IGF molecules.
Sm/IGF BPS of sizes similar to those observed here have been identified in rat serum both by column chromatography (Moses et al., 1976) and affinity cross-linking (D'Ercole and . The 40K complex we observed appears similar or identical to the non-GH-dependent 40K complex observed in rat serum. This BP was recognized by antibodies raised against a 32K BP purified from BRL-3A cells (Mottola et al., 1986) . Romanus et al. (1986) also purified a BP of near-identical size (33K) from BRG3A CM, and showed that antibodies raised against it recognized the 40K non-GH-dependent BP complex in rat serum. Our finding that the 40K complex elaborated by astroglial cells is not increased in apparent abundance by incubation with GH further supports our conclusion that the 33-35K BP in this complex is the same or very similar to the bloodborne non-GH-dependent BP. The identity of the 45K complex is less clear. We have observed a similarly sized (49K) Sm/IGF-BP complex by affinity cross-linking of rat serum . Our finding that the BP represented in this species can bind insulin (albeit with low affinity) argues that this BP is unique, because, to our knowledge, no other Sm/IGF BP has been reported as recognizing insulin even at high concentrations. Gjedde (1967) , however, has reported that insulin binds to cat serum proteins that migrate at a similar molecular size on open-bed columns. The very low apparent affinity of the BP in the 45K complex makes it unlikely to function as a circulating carrier of insulin.
The tissue culture technique we used results in a relatively pure (> 90%) population of polygonal astroglial cells by morphological and immunocytochemical criteria (McCarthy and de Vellis, 1980) , and thus provides evidence that the BPS characterized in this study were synthesized by these cells. However, we cannot exclude the contribution of other nonastrocytic cells, e.g., fibroblasts, oligodendrocytes, and ependymal cells, which form less than 5% of the cells. The confirmation of the presence of cell types that produce these BPS awaits in situ hybridization analysis with specific IGF BP cDNA probes. Further evidence of synthesis comes from the findings that there is an apparent reduction in BP following serum starvation, and an apparent progressive increase in BP when cells are incubated in SF-BME can be detected by radioimmunoassay in the serum of rats. The level of type II receptor appears to be developmentally regulated. The sizes of the binding moieties are 2 10 and 240 kDa under nonreduced and reduced conditions, respectively, and, therefore, are consistent with the sizes of the cell surface receptors under similar conditions. However, they are different from the sizes of the astroglial BPS described in this study.
Our data clearly demonstrate that addition of the BRL-3A BP to astroglia inhibits the action of Sm-C/IGF I by preventing Sm-C/IGF I binding to its cell surface receptors. Because this BP is similar to the 33K species elaborated by astroglia, we assume that the latter would exert the same effect. Other influences of BP, however, seem possible. Elgin et al. (1987) have recently shown that a 35K BP purified from human amniotic fluid can potentiate the mitogenic action of Sm-C/IGF I in cultured fibroblasts, possibly by delivering Sm-C/IGF I to its cell surface receptors. We have shown that human fibroblasts secrete a BP of approximately 35K Da that associates with the cell surface and modulates the abundance of Sm-C/IGF I on the cell surface, including Sm-C/IGF I receptor binding (Clemmons et al., 1986) . Using identical procedures, however, we did not observe rat astroglial BPS to be associated with the astroglial cell surface (unpublished observation). It seems possible that BPS that are secreted into the media have different effects than those capable of associating with the cell surface.
Herein, we have shown that neonatal rat astroglia secrete binding proteins that may modulate the biologic actions of Sml IGFs. Binoux et al. (198 1) have shown that pituitary and brain explants produce Srn/IGFs. Specific Sm/IGF receptors have been demonstrated on neuronal (Burgess et al., 1987) and glial (Han et al., 1987) cells, and astroglia and oligodendroglia have been shown to respond to the mitogenic actions of Sm/IGFs (McMorris et al., 1986; Han et al., 1987) . Taken together, these data point to a role for the Sm/IGFs in the development of glial cells. The present study is consistent with this hypothesis and suggests that the regulation of growth of glial cells may involve a complex mechanism of interactions between Sm/IGFs, their receptors and BPS.
